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Objectives: The purpose of this study was to evaluate cancer risks in the Korean semiconductor industry.
Methods: A retrospective cohort study was performed in eight semiconductor factories between 1998 and 2008. The number of 
subjects was 113,443 for mortality and 108,443 for incidence. Standardized mortality ratios (SMR) and standardized incidence ra-
tios (SIR) were calculated.
Results: The SMR of leukemia was 0.39 (95% Confidence Interval 0.08-1.14) in males (2 cases) and 1.37 (0.55-2.81) in females (7 
cases). The SMR of non-Hodgkin’s lymphoma (NHL) was 1.33 (0.43-3.09, 5 cases) in males and 2.5 (0.68-6.40, 4 cases) in females. 
The SIR of leukemia was 0.69 (0.30-1.37, 8 cases) in males and 1.28 (0.61-2.36, 10 cases) in females. The SIR of NHL in females was 
2.31 (1.23-3.95, 13 cases) and that of thyroid cancer in males was 2.11 (1.49-2.89, 38 cases). The excess incidence of NHL was sig-
nificant in female assembly operators [SIR=3.15 (1.02-7.36, 5 cases)], but not significant in fabrication workers. The SIR of NHL in 
the group working for 1-5 years was higher than the SIR of NHL for those working for more than five years. The excess incidence 
of male thyroid cancer was observed in both office and manufacturing workers.
Conclusion: There was no significant increase of leukemia in the Korean semiconductor industry. However, the incidence of NHL 
in females and thyroid cancer in males were significantly increased even though there was no definite association between work 
and those diseases in subgroup analysis according to work duration. This result should be interpreted cautiously, because the 
majority of the cohort was young and the number of cases was small.
Key Words: Semiconductors, Leukemia, Lymphoma, Cancer, Cohort studies
Introduction
Concern that there might be leukemia clusters in a semicon-
ductor company in Korea was first expressed in 2007 [1] by a 
workers’ support group and this was covered in the media. The 
Occupational Safety and Health Research Institute (OSHRI) of 
the Korea Occupational Safety and Health Agency (KOSHA) 
conducted an environmental assessment of  the semiconduc-
tor company in 2008 in order to determine whether Group 1 
occupational carcinogens based on the international agency 
for research on cancer (IARC), such as benzene and ionizing 
radiation, were related with malignant lymphohematopoietic 
(LHP) cancers. Known occupational carcinogens were not 
found at the workplace, and benzene was below the detection 
limit (1 ppb) and ionizing radiation was similar to the natural 
background level [1,2]. However, another worker, who had 
worked with the first case, subsequently died from leukemia. 
From 2007 to 2010, OSHRI investigated seven cases of  ma-
lignant LHP disorders to evaluate work-relatedness in the 
semiconductor industry, which were requested by the Korea 
Workers’ Compensation and Welfare Service (COMWEL) [1]. 
Considering subsequent LHP cancer cases, the Epidemiologi-
cal Investigation Review Board of OSHRI recommended that 
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a nationwide epidemiological investigation was necessary to 
evaluate the risk of LHP cancer in the semiconductor industry. 
A nationwide epidemiological investigation by OSHRI was 
conducted in 2008.
There were similar cases in the U.S. firm IBM and the Na-
tional Semiconductor in the UK. In 1985, a chemist working in 
the IBM research facility in San Jose, California, revealed that 
there was a cluster of  cancers in his colleagues [3]. In 1996, 
128 former IBM workers and their families, including 11 de-
ceased workers by cancer, sued the chemical suppliers insisting 
they had suffered adverse health effects, including cancers and 
miscarriages, from work exposure to hazardous chemicals [4]. 
In 1998, concerns about a suspicious cluster of cancers in the 
Greenock Plant of National Semiconductor Limited in the UK 
was expressed in the form of workers’ support group actions, 
media coverage, and parliamentary activity [5]. In response to 
these issues of semiconductor workers’ cancers, epidemiologi-
cal studies were performed, but a definitive association between 
work in semiconductor manufacturing and cancers was not 
found [5-8]. Aside from studies targeting these workforces, 
there were some others exploring cancer risk in the semicon-
ductor industry, but they have not provided consistent evidence 
that exposures in the industry were associated with cancer [9-
11]. 
The aim of this study was to determine the incidence and 
mortality rates of cancers in Korean semiconductor workers in 




Subjects were current and former workers of eight factories and 
each factory belonged to one of five semiconductor manufac-
turers from the members of the Korea Semiconductor Industry 
Association (KSIA). KSIA included 9 semiconductor device 
manufacturers and many other related companies, for example 
parts making, semiconductor architecture, and semiconductor 
equipment. The five companies selected to participate in the 
study comprised all of  the semiconductor manufacturers in 
Korea that performed fabrication processes. The semiconduc-
tor manufacturing process is generally composed of fabrication 
and assembly. Fabrication processes were composed of the fol-
lowing six steps: diffusion, lithography, etching, ion implanta-
tion, chemical vapor deposition (CVD), and metallization [2]. 
Four factories were fabrication facilities, one was for assembly 
and three factories had both fabrication and assembly process-
es. These 8 factories were all the factories of the 5 manufactur-
ers except the factories outside Korea.
The cohort included workers who had worked at any of 
the eight factories for more than one day between 1998 and the 
last year of  the study (2008 for mortality, 2007 for incidence 
analysis), and who had a record containing information on 
birth date, gender, resident registration number (personal identi-
fication number), hiring date, job description, and department. 
Follow-up for workers was started in 1998 because worker 
personnel records were available from 1998 in all factories al-
though most of the factories were established before 1998. One 
of the factories was opened in 1999, 2 of them were opened in 
1997, and the others were established in the 1970’s or 1980’s. 
The last year of the cohort for mortality rates was 2008, which 
was when death certificate data were available, while that for 
incidence rates was 2007 when the cancer registry data were 
available. Individual exposure data were not available, but 
workers in the same subgroups were assumed to have the same 
exposures. There were some industrial hygiene monitoring 
data, but it was based on specific places and processes, like Oxi-
dation, Lithography, and so on. These data could not be linked 
with workers personal data because there was no information 
regarding working place or detailed process. 
Cohorts were first classified into office and manufacturing 
workers, and then manufacturing workers were divided into 
operators, engineers (process engineers and service engineers), 
supervisors, and utility workers. Operators and engineers were 
the main workers working in the clean-room. Operators typi-
cally handle manufacturing equipment, and service engineers 
maintain the manufacturing equipment. Process engineers 
improve the process stream by programming. Supervisors are 
close to office workers but they occasionally go in the clean-
room. Utility workers are not directly involved in the manufac-
turing process, but they maintain general utilities for facilities 
outside the clean-room, like electricity and gas supply. Workers 
who had worked at any time in the manufacturing process 
were classified as manufacturing workers, while workers that 
had never worked in the manufacturing process were classified 
as office workers. Among manufacturing workers, employees 
that had worked in two or more jobs were assigned as workers 
in those jobs, too. Consequently, a worker who changed from 
operator to engineer or vice versa was assigned to both job 
categories. Manufacturing workers were categorized to fabrica-
tion or assembly according to their experience of having ever 
worked in those processes. Also, workers who had work his-
tory in both fabrication and assembly were categorized to both 
processes. Grouping of cohorts was performed in consultation 
with the Human Resource Teams and the Occupational Health 
Departments of surveyed manufacturers. 
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Table 1. Number of subjects by selected characteristics for mortality and incidence analysis













Total* 48,589 (100.0) 64,854 (100.0) 113,443 (100.0) 46,826 (100) 62,107 (100) 108,933 (100)
Birth 
 year
< 1940        22 (0.0)          2 (0.0)          24 (0.0)        22 (0.0)          2 (0.0)          24 (0.0)
1940-1949      266 (0.5)        52 (0.1)        318 (0.3)      258 (0.6)        52 (0.1)        310 (0.3)
1950-1959   1,963 (4.0)        89 (0.1)     2,052 (1.8)   1,941 (4.1)        89 (0.1)     2,030 (1.9)
1960-1969 12,033 (24.8)      341 (0.5)   12,374 (10.9) 11,999 (25.6)      339 (0.5)   12,338 (11.3)
1970-1979 25,271 (52.0) 20,114 (31.0)   45,385 (40.0) 24,858 (53.1) 20,068 (32.3)   44,926 (41.2)
1980-1989   9,024 (18.6) 43,652 (67.3)   52,676 (46.4)   7,748 (16.5) 41,429 (66.7)   49,177 (45.1)
≥ 1990        10 (0.0)      604 (0.9)        614 (0.5)          0 (0.0)      128 (0.2)        128 (0.1)
Job Office workers 11,350 (23.4)   3,889 (6.0)   15,239 (13.4) 10,759 (23)   3,735 (6)   14,494 (13.3)
Manufacturing workers 37,234 (76.6) 60,965 (94.0)   98,199 (86.6) 36,062 (77) 58,372 (94)   94,434 (86.7)
Hire date < 1991   9,222 (19.0)   1,353 (2.1)   10,575 (9.3)   9,208 (19.7)   1,352 (2.2)   10,560 (9.7)
1992-1997 15,218 (31.3) 17,209 (26.5)   32,427 (28.6) 15,210 (32.5) 17,204 (27.7)   32,414 (29.8)
1998-2003 10,245 (21.1) 22,723 (35)   32,968 (29.1) 10,239 (21.9) 22,717 (36.6)   32,956 (30.3)
≥ 2004 13,904 (28.6) 23,569 (36.3)   37,473 (33.0) 12,169 (26) 20,834 (33.5)   33,003 (30.3)
Years 
  worked
Unknown          2 (0.0)        10 (0.0)          12 (0.0)        66 (0.1)      775 (1.2)        841 (0.8)
< 1 month      134 (0.3)   1,516 (2.3)     1,650 (1.5)      162 (0.3)   2,007 (3.2)     2,169 (2)
1 month-1 year   1,776 (3.7) 10,665 (16.4)   12,441 (11.0)   1,714 (3.7)   9,288 (15)   11,002 (10.1) 
1-5 year 15,540 (32) 29,719 (45.8)   45,259 (39.9) 14,213 (30.4) 27,560 (44.4)   41,773 (38.3)
5-10 year 13,504 (27.8) 16,846 (26.0)   30,350 (26.8) 13,137 (28.1) 16,475 (26.5)   29,612 (27.2)




Total manufacturing workers 32,946 (67.8) 48,022 (74.0)   80,968 (71.4) 32,037 (68.4) 46,042 (74.1)   78,079 (71.7)
Operator   1,784 (3.7) 44,137 (68.1)   45,921 (40.5)   1,758 (3.8) 42,261 (68)   44,019 (40.4)
Service engineer 14,954 (30.8)   2,541 (3.9)   17,495 (15.4) 14,513 (31)   2,522 (4.1)   17,035 (15.6)
Process engineer 11,728 (24.1)   1,754 (2.7)   13,482 (11.9) 11,384 (24.3)   1,682 (2.7)   13,066 (12)
Supervisor   3,324 (6.8)   2,186 (3.4)     5,510 (4.9)   3,303 (7.1)   2,168 (3.5)     5,471 (5)
Utility   4,090 (8.4)   1,315 (2.0)     5,405 (4.8)   3,916 (8.4)   1,276 (2.1)     5,192 (4.8)
Assembly Total manufacturing workers   6,465 (13.3) 19,767 (30.5)   26,232 (23.1)   6,184 (13.2) 19,024 (30.6)   25,208 (23.1)
Operator      661 (1.4) 19,038 (29.4)   19,699 (17.4)      612 (1.3) 18,304 (29.5)   18,916 (17.4)
Service engineer   4,118 (8.5)   1,523 (2.3)     5,641 (5.0)   3,937 (8.4)   1,512 (2.4)     5,449 (5) 
Process engineer   1,611 (3.3)      146 (0.2)     1,757 (1.5)   1,565 (3.3)      142 (0.2)     1,707 (1.6)
Supervisor      884 (1.8)      830 (1.3)     1,714 (1.5)      871 (1.9)      824 (1.3)     1,695 (1.6) 
Utility      436 (0.9)      406 (0.6)        842 (0.7)      434 (0.9)      400 (0.6)        834 (0.8)
Person-years     389,105      443,406     832,512      340,220      378,630      718,850
Cases            153            114            267            201            145            346†
*The total might be less or more than the sum of the number of employees at each stratum because there were workers who were classified 
into more than one stratum or classified as unknown. 
†Six persons of the cases in incidence analysis had double primary cancers.
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Eligible workers were 113,443 for mortality and 108,933 for in-
cidence (Table 1). The proportion of females was 57% of both 
cohorts. Age and occupation were differentiated by sex. The 
most common age group was 30-39 years old for males and 20-
29 years old for females as of 2009. Among male workers, 75% 
were manufacturing workers, and among female workers, 94% 
were in the mortality cohort. For female works, 74% were in-
volved in the fabrication process and 31% were involved in the 
assembly process, while the respective values for male workers 
were 68% and 13%, respectively.
When the mortality study ended in 2008, 0.2% of work-
ers were deceased and the study subjects observed represented 
832,512 person-years. The overall mean length of follow-up for 
mortality analysis was 7.3 years.
In the incidence study, 0.3% of  cohorts were registered 
as having cancers until 2007, and the observed study subjects 
represented 718,849 person-years. The overall mean length of 
follow-up for incidence analysis was 6.6 years.
Data matching process
The cohort dataset was sent to the National Statistical Office 
(NSO) and the Korea Central Cancer Registry (KCCR) in or-
der to match the deaths or cancers between the two datasets. 
The NSO has reported national statistics on the cause of death 
based on death certificates annually since 1992. The cancer 
registry has been operating nationwide since 1980 and covers 
more than 95% cases of  cancer that occurred in Korea. It is 
assumed that all of  the unmatched persons with these regis-
tries remained alive at the end of  study. That is we consider 
there is no follow-up loss for these individuals. The NSO and 
KCCR provided OSHRI the information on matched cases 
of the cause of death or type of cancer by the closing date of 
the study according to the classification of  the International 
Classification of  Diseases (ICD)-10. The matched data were 
given to OSHRI after trimming the personal information to 
maintain confidentiality by deleting some digits of the resident 
registration number, or by changing the birth or hired date year. 
The identity of each case was protected because in most cases 
there were at least 2 workers with the same sex, age, employed 
year, and company. When trimming the date of hire, July 15th 
of each year of employment was used to calculate the person-
years. This matching process with death or cancer incidence 
data was performed independently because both NSO and 
KCCR have their own data protection policy that they should 
not provide any information that makes it possible to identify 
patients. Consequently it was impossible to link the death and 
cancer incidence information of the subjects. Sixty-three work-
ers who had been diagnosed with any kind of cancer before en-
tering the cohort were excluded. Appropriate ethical approval 
was obtained, and the data for the study were treated in accor-
dance with current legislation on personal information security.
Mortality and incidence ratios calculation
The cancer mortality and incidence ratios were calculated for 
all subjects and subgroups and they were classified by work 
duration, job categories, fabrication/assembly process, and the 
first year of employment. Standardized mortality ratios (SMRs) 
were calculated with the observed cases of deaths and divided 
by expected cases of deaths based on deaths in the Korean gen-
eral population, which was standardized by sex, age (5-year age 
groups from 15 to 84), and calendar period (3 calendar periods 
of 1998-2001, 2002-2005, and 2006-2008). 
The standardized incidence ratios (SIRs) of  the cohort 
was calculated with the observed cases of cancers divided by 
the expected cases of cancers based on the cancer incidence of 
the Korean general population, which was standardized by sex, 
age (5-year age groups from 15 to 89), and calendar period (2 
calendar periods of 1998-2002 and 2003-2007). Mortality and 
incidence rates of the reference population in the mid-year of 
each calendar period were used. 
p-values and 95% confidence intervals (95% CIs) were 
calculated based on the assumption that deaths and cancers 
occurred with a Poisson distribution. Statistical analysis were 
done by PAMCOMP (Person-years and mortality computation 
program) [12] and LTAS (Life Table Analysis System) [13].
Results
Mortality analysis
The most common causes of  death were injury, poisoning, 
and certain other consequences of  external causes (S00-T98) 
(140 cases), followed by neoplasms (C00-D48) (75 cases) and 
disease of the circulatory system (I00-I99) (25 cases). The SMR 
for all cause mortality was 0.25 (95% CI 0.21-0.29) in males 
and 0.66 (95% CI 0.55-0.80) in females (Table 2). Mortality of 
most cancers was lower than expected. The SMR of leukemia 
was 0.39 (95% CI 0.08-1.14) in males with 2 deaths, and 1.37 
(95% CI 0.55-2.81) in females with 7 deaths. The SMR of non-
Hodgkin’s lymphoma (NHL) increased to 1.33 (95% CI 0.43-
3.09) in males with five cases and 2.5 (95% CI 0.68-6.40) in 
females with 4 cases, but they were not statistically significant.
Cancer incidence analysis
The SIR for all malignant neoplasm was 0.86 (95% CI 0.74-
0.98) in males and 0.88 (95% CI 0.74-1.03) in females (Table 
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3). The SIR of NHL in females increased to 2.31 (95% CI 1.23-
3.95), and it was statistically significant. The SIR of  thyroid 
cancer in males increased to 2.11 (95% CI 1.49-2.89). The SIR 
of  leukemia was 0.69 (95% CI 0.30-1.37) in males and 1.28 
(95% CI 0.61-2.36) in females. Some groups of  cancer also 
showed excessive incidence ratios, but they were not statisti-
cally significant, and they follow: lip, oral cavity, and pharynx 
for men (cases = 8, SIR 1.25, 95% CI 0.54-2.46), colon cancer 
for women (cases = 4, SIR 1.52, 95% CI 0.41-3.89), malignant 
melanoma for men (cases = 3, SIR 2.9, 95% CI 0.60-8.47), kid-
ney cancer for men (cases = 13, SIR 1.82, 95% CI 0.97-3.12), 
corpus uteri cancer for women (cases = 4, SIR 1.53, 95% CI 
0.42-3.92) and brain and central nervous system for men (cases 
= 9, SIR 1.37, 95% CI 0.62-2.59).
The SIR of leukemia in female workers slightly increased 
(cases = 10, SIR 1.28, 95% CI 0.61-2.36) (Table 4). The excess 
slightly decreased in female manufacturing workers (cases = 8, 
SIR 1.11, 95% CI 0.48-2.18). Among manufacturing workers, 
the excess slightly increased in assembly workers (cases = 4, 
SIR 1.69, 95% CI 0.46-4.32). The excess was greater in female 
workers employed before 1991 (cases = 2, SIR 5.92, 95% CI 
0.72-21.37) than those employed after 1991 but not statistically 
significant. The number of cases in female workers employed 
before 1991 was only 2 and the confidence interval was very 
wide. In the current study, factory- or company-specific analy-
ses were not possible due to the small number of cases. Among 
the 5 companies included, the number of cases ranged from 0 
to 5 for males and 0 to 7 for females (not shown in tables).
Table 2. Observed number of deaths of specific types of cancer, SMRs and 95% confidence interval
Disease group (ICD-10)
Male Female
Obs SMR 95% CI Obs SMR 95% CI
All cause 153 0.25 (0.21-0.29) 114 0.66 (0.55-0.80)
[C00-C97] Malignant neoplasm   48 0.44 (0.32-0.58)   24 0.79 (0.51-1.18)
[C00-C14] Lip, oral cavity and pharynx     2 1.05 (0.13-3.81)     0 0 (0.00-13.88)
[C15-C26] Digestive organs   25 0.36 (0.23-0.53)     9 0.91 (0.42-1.73)
  (C16) Stomach    10 0.5 (0.24-0.91)     5 0.8 (0.26-1.86)
  (C18) Colon      1 0.26 (0.01-1.44)     3 2.87 (0.59-8.39)
  (C22) Liver and intrahepatic bile ducts    11 0.35 (0.17-0.62)     1 0.85 (0.02-4.71)
  (C23-C24) Gallbladder & other and unspecified parts of biliary tract      1 0.44 (0.01-2.44)     0 0 (0.00-20.60)
  (C25) Pancreas      2 0.53 (0.06-1.93)     0 0 (0.00-10.31)
[C30-C39] Respiratory and intrathoracic organs     3 0.23 (0.05-0.67)     1 0.54 (0.01-3.00) 
  (C33-C34) Trachea & Malignant neoplasm of bronchus and lung      3 0.25 (0.05-0.74)     1 0.63 (0.02-3.53)
[C40-C41] Bone and articular cartilage     1 1.08 (0.03-5.99)     0 0 (0.00-3.76)
[C43-C44] Skin     1 1.36 (0.03-7.59)     0 0 (0.00-8.35)
[C45-C49] Mesothelial and soft tissue     1 0.7 (0.02-3.90)     0 0 (0.00-3.96)
[C50-C50] Breast     1 8.56 (0.22-47.70)     2 0.84 (0.10-3.02)
[C51-C58] Female genital organs -    -         -     0 0 (0.00-1.64)   
[C60-C63] Male genital organs     0 0 (0.00-5.46) -    -         -
[C64-C68] Urinary tract     1 0.55 (0.01-3.06)     0 0 (0.00-12.464)
[C70-C72] Brain and other parts of central nervous system     4 0.92 (0.25-2.35)     1 0.34 (0.01-1.87)
  (C73) Thyroid gland      0 0 (0.00-14.21)     0 0 (0.00-64.24)
[C81-C96] Lymphoid, haematopoietic and related tissue     8 0.64 (0.28-1.26)   11 1.56 (0.78-2.78)
  (C82-C85) Non-Hodgkin’s lymphoma      5 1.33 (0.43-3.09)     4 2.5 (0.68-6.40) 
  (C91-C95) Leukaemia      3 0.39 (0.08-1.14)     7 1.37 (0.55-2.81)
Obs: observed, SMR: standardized mortality ratio, CI: confidence interval.
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The SIR of NHL significantly increased in females, espe-
cially in manufacturing workers (Table 5). Among manufactur-
ing workers, the excess increased more in assembly operators 
(cases = 5, SIR 3.1, 95% CI 1.02-7.36). The excess was highest 
in female workers employed after 2004 (cases = 3, SIR 5.28, 
95% CI 1.09-15.44) among the groups according to the first 
Table 3. Observed number of cases of specific types of cancer, SIRs and 95% confidence interval
Disease group (ICD-10)
Male Female
Obs SIR 95% CI Obs SIR 95% CI
[C00-C97] Malignant neoplasm 201 0.86 (0.74-0.98) 145 0.88 (0.74-1.03)
[C00-C14] Lip, oral cavity and pharynx     8 1.25 (0.54-2.46)     1 0.31 (0.01-1.75)
[C15-C26] Digestive organs   88 0.68 (0.54-0.83)   19 0.87 (0.52-1.36)
  (C15) Oesophagus      1 0.58 (0.01-3.26)     0 0 (0.00-55.12)
  (C16) Stomach    44 0.84 (0.61-1.13)   12 0.93 (0.48-1.62)
  (C18) Colon      9 0.63 (0.29-1.20)     4 1.52 (0.41-3.89)
  (C19-C20) Rectosigmoid junction & rectum    12 0.83 (0.43-1.45)     1 0.48 (0.01-2.67)
  (C22) Liver and intrahepatic bile ducts    18 0.46 (0.27-0.73)     1 0.39 (0.01-2.18)
  (C23-C24) Gallbladder & other and unspecified parts of biliary tract      2 0.75 (0.09-2.71)     0 0 (0.00-8.54)
  (C25) Pancreas      2 0.49 (0.06-1.77)     0 0 (0.00-5.31)
[C30-C39] Respiratory and intrathoracic organs   10 0.55 (0.26-1.01)     1 0.31 (0.01-1.73)
  (C33-C34) Trachea & Malignant neoplasm of bronchus and lung      7 0.48 (0.19-0.98)     1 0.46 (0.01-2.54)
[C40-C41] Bone and articular cartilage     4 2 (0.54-5.12)    0 0 (0.00-1.83)
[C43-C44] Skin    6 1.56 (0.57-3.40)     0 0 (0.00-2.06)
  (C43) Malignant melanoma of skin      3 2.9 (0.60-8.47)    0 0 (0.00-6.83)
[C45-C49] Mesothelial and soft tissue     1 0.31 (0.01-1.75)     1 0.4 (0.01-2.23)
[C50-C50] Breast     0 0 (0.00-16.71)    16 0.77 (0.44-1.26)
[C51-C58] Female genital organs -     -         -   20 0.84 (0.51-1.29)
  (C53) Cervix uteri  -     -         -     3 0.31 (0.06-0.91)
  (C54) Corpus uteri  -     -         -     4  1.53 (0.42-3.92)
  (C56) Ovary  -     -         -     9 0.92 (0.42-1.75)
[C60-C63] Male genital organs     1 0.19 (0.00-1.04) -     -         -
[C64-C68] Urinary tract   17 1.36 (0.79-2.18)     0 0 (0.00-2.17)
  (C64) Kidney, except renal pelvis    13 1.82 (0.97-3.12)     0 0 (0.00-3.04)
  (C67) Bladder      5 1.06 (0.34-2.47)     0 0 (0.00-7.71)
[C70-C72] Brain and other parts of central nervous system     9 1.37 (0.62-2.59)      1 0.22 (0.01-1.22)
[C73-C75] Thyroid and other endocrine glands    41 2.19* (1.57-2.97)   63 1 (0.77-1.28)
  (C73) Thyroid gland    38 2.11* (1.49-2.89)   62 0.99 (0.76-1.27)
[C81-C96] Lymphoid, haematopoietic and related tissue   19 0.78 (0.47-1.22)   23 1.54 (0.98-2.31)
  (C81) Hodgkin’s disease      1 0.9 (0.02-5.00)     0 0 (0.00-2.55)
  (C82-C85) Non-Hodgkin’s lymphoma    10 0.93 (0.45-1.71)   13 2.31* (1.23-3.95)
  (C91-C95) Leukaemia      8 0.69 (0.30-1.37)   10 1.28 (0.61-2.36)
Obs: observed, SIR: standardized incidence ratio, CI: confidence interval.
*Statistically significant at the 2-sided 5% level of significance.
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year employed. Also, the excess was greater in female workers 
who worked for 1-5 years (cases = 6, SIR 2.94, 95% CI 1.08-
6.39) than those who worked for 5-10 years and more than 10 
years. 
The excess of  male thyroid cancer was observed (cases 
= 38, SIR 2.11, 95% CI 1.49-2.89), and this data was also in-
vestigated for male office workers (cases = 15, SIR 2.75, 95% 
CI 1.54-4.54). Among manufacturing workers, the excess was 
significant for process engineers (cases = 12, SIR 2.50, 95% CI 
1.29-4.38). The excess was greatest for men first employed in 
1992-1997 (cases = 20, SIR 2.78, 95% CI 1.70-4.30) among the 
groups according to the first year employed. The excess was 
significant for men who worked for more than 10 years (cases 
= 23, SIR 2.30, 95% CI 1.46-3.46).
The SIR of kidney cancer increased in males (cases = 13, 
SIR 1.82, 95% CI 0.97-3.12) and the SIR was marginally sig-
nificant. But there were no cases of kidney cancer in females.
Discussion
The semiconductor industry is chemical-intensive, especially 
for the wafer fabrication process. Once it was thought to be 
a “clean” industry because of  the clean-room, but there was 
concern of  continuous multiple chemical exposures to work-
ers from recirculated air for particle control [3]. Actually, there 
were some suspicious disease clusters mainly focused in can-
Table 4. Leukemia (C91-C95) incidence : numbers and SIRs by selected subgroups
Male Female
Obs SIR 95% CI Obs SIR 95% CI
Total* 8 0.69 (0.30-1.37) 10   1.28 (0.61-2.36)
Job Office workers 2 0.63 (0.08-2.27) 2   3.49 (0.42-12.60)
Manufacturing workers 6 0.72 (0.26-1.56) 8   1.11 (0.48-2.18)
Manufacturing 
  worker
Assembly 0 0 (0.00-2.50) 4   1.69 (0.46-4.32)
Fabrication 6 0.8 (0.29-1.75) 7   1.22 (0.49-2.52)
FAB manufacturing 
  worker
Operator 1 2.06 (0.05-11.46) 6   1.15 (0.42-2.50)
Service engineer 5 1.57 (0.51-3.66) 1   3.45 (0.09-19.23)
Process engineer 1 0.34 (0.01-1.90) 0   0 (0.00-16.79)
Supervisor 0 0 (0.00-3.59) 1   2.40 (0.06-13.38)
Utility 1 1.16 (0.03-6.47) 1   6.44 (0.16-35.87)
Assembly 
  manufacturing 
  worker
Operator 0 0 (0.00-21.10) 4   1.78 (0.49-4.56)
Service engineer 0 0 (0.00-4.26) 1   5.78 (0.15-32.20)
Process engineer 0 0 (0.00-8.71) 0   0 (0.00-222.46)
Supervisor 0 0 (0.00-13.60) 0   0 (0.00-22.77)
Utility 0 0 (0.00-29.44) 1 22.14 (0.56-123.38)
Hire date < 1991 5 1.43 (0.46-3.33) 2   5.92 (0.72-21.37)
1992-1997 3 0.61 (0.12-1.77) 4   1.15 (0.31-2.95)
1998-2003 0 0 (0.00-1.61) 3   0.98 (0.20-2.87)
≥ 2004 0 0 (0.00-4.70) 1   1.06 (0.03-5.89)
Years worked 1 month-1 year 0 0 (0.00-11.07) 1   1.13 (0.03-6.28)
1-5 year 0 0 (0.00-1.98) 4   1.38 (0.37-3.52)
5-10 year 3 0.94 (0.19-2.74) 2   0.79 (0.10-2.86)
≥ 10 year 5 0.82 (0.27-1.92) 3   2.46 (0.51-7.20)
Obs: observed, SIR: standardized incidence ratio, CI: confidence interval, FAB: fabrication.
*The total might be less or more than the sum of the number of cases at each stratum because there were workers who were classified into 
more than one stratum or classified as unknown.
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cers, reproductive disorders, and rare diseases in a few countries 
since the semiconductor industry began. For this reason, some 
studies were performed to investigate cancer risk [5-8], but a 
definitive association between work in semiconductor manu-
facturing and cancers was not found. This study was performed 
in response to leukemia concerns in the Korean semiconductor 
industry [1], and there is still a need for a broad epidemiologi-
cal investigation on cancer risk of  semiconductor workers 
throughout the world.
Overall mortality experience
The overall pattern of mortality and cancer incidence showed 
a substantial decrease in deaths from all causes (SMR 0.25, CI 
0.21-0.29) and all cancers (SMR 0.44, CI 0.32-0.58) among 
men, and a less substantial decrease among women for all 
causes (SMR 0.66, CI 0.55-0.80) and all cancers (SMR 0.79, 
CI 0.51-1.18). The cancer incidence (all malignant neoplasm) 
was slightly lower than expected in both men (SIR 0.86, CI 
0.74-0.98) and women (SIR 0.88, CI 0.74-1.03). From these 
results, an apparent healthy worker effect was inferred for both 
males and females, and it was stronger for males. Substantial 
members of the cohort were quite young and active workers, 
so a considerable healthy worker effect was not surprising. In 
addition, these semiconductor workers were expected to belong 
Table 5. Non-Hodgkin’s lymphoma (C81-C85) incidence : numbers and SIRs by selected subgroups
Male Female
Obs SIR 95% CI Obs SIR 95% CI
Total† 10 0.93 (0.45-1.71) 13 2.31* (1.23-3.95)
Job Office workers   2 0.60 (0.07-2.16) 0 0 (0.00-7.64)
Manufacturing workers   8 1.08 (0.47-2.12) 13 2.53* (1.34-4.32)
Manufacturing worker Assembly   0 0 (0.00-2.77) 5 2.97 (0.96-6.92)
Fabrication   8 1.21 (0.52-2.38) 8 1.96 (0.85-3.86)
FAB manufacturing 
  worker
Operator   1 2.15 (0.05-11.98) 7 1.91 (0.77-3.94)
Service engineer   3 1.13 (0.23-3.32) 0 0 (0.00-17.65)
Process engineer   2 0.74 (0.09-2.67) 0 0 (0.00-21.26)
Supervisor   2 1.90 (0.23-6.86) 0 0 (0.00-11.38)
Utility   2 2.67 (0.32-9.64) 0 0 (0.00-31.72)
Assembly 
  manufacturing 
  worker
Operator   0 0 (0.00-20.57) 5 3.15* (1.02-7.36)
Service engineer   0 0 (0.00-5.12) 0 0 (0.00-31.27)
Process engineer   0 0 (0.00-9.07) 0 0 (0.00-288.05)
Supervisor   0 0 (0.00-13.26) 0 0 (0.00-29.95)
Utility   0 0 (0.00-30.49) 0 0 (0.00-103.19)
Hire date < 1991   3 0.76 (0.16-2.21) 1 3.19 (0.08-17.79)
1992-1997   4 0.92 (0.25-2.37) 6 2.26 (0.83-4.92)
1998-2003   1 0.53 (0.01-2.95) 3 1.44 (0.30-4.20)
≥ 2004   2 3.45 (0.42-12.46) 3 5.28* (1.09-15.44)
Years worked 1 month-1 year   0 0 (0.00-12.47) 0 0 (0.00-6.34)
1-5 year   4 2.50 (0.68-6.41) 6 2.94* (1.08-6.39)
5-10 year   2 0.71 (0.09-2.57) 5 2.69 (0.87-6.28)
≥ 10 year   4 0.66 (0.18-1.70) 1 1.03 (0.03-5.75)
Obs: observed, SIR: standardized incidence ratio, CI: confidence interval, FAB: fabrication.
*Statistically significant at the 2-sided 5% level of significance.
†The total might be less or more than the sum of the number of cases at each stratum because there were workers who were classified into 
more than one stratum or classified as unknown.
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to the high socioeconomic status (SES) group because they are 
all regular workers of  large enterprises. The overall low mor-
tality of semiconductor workers in this study is compatible to 
previous studies on semiconductor workers in the US (SMR 
0.68, 95% CI 0.66-0.71) [6], UK (SMR 0.45 for male, 0.73 for 
female) [5,14], and in Taiwan (SMR 0.27, 95% CI 0.22-0.33)
[15].
Entering a company at an early age and the shorter work-
ing period of female workers might be one of the explanations 
for the mortality difference between male and female work-
ers. Another possible explanation of the gender difference of 
mortality might result from stronger healthy worker effect for 
males than females. This is because the female general popula-
tion is healthier than the male general population, for example, 
females drink and smoke less and the average life span of a fe-
male Korean is 7 year longer than that of a male. Mortality was 
lower in males than in female workers, a difference also seen in 
the UK [5] and Taiwan studies [15]. The majority (64%) of fe-
male workers had worked less than 5 years, whereas only 36% 
of male workers worked the same amount of time. The most 
common age group for males was 30-39 and 20-29 for females 
at the end of the study.
In our study, the cancer incidence difference between 
males and females was not shown, and this finding was also 
Table 6. Thyroid cancer (C73) incidence : numbers and SIRs by selected subgroup
Male Female
Obs SIR 95% CI Obs SIR 95% CI
Total† 38 2.11* (1.49-2.89) 62 0.99 (0.76-1.27)
Job Office workers 15 2.75* (1.54-4.54) 10 1.67 (0.80-3.08)
Manufacturing workers 23 1.83* (1.16-2.74) 52 0.92 (0.69-1.21)
Manufacturing worker Assembly   4 1.82 (0.50-4.66) 17 0.91 (0.53-1.46)
Fabrication 20 1.77* (1.08-2.74) 37 0.83 (0.58-1.14)
FAB manufacturing 
  worker
Operator   0 0 (0.00-5.21) 29 0.74 (0.50-1.07)
Service engineer   8 1.81 (0.78-3.56) 1 0.42 (0.01-2.31)
Process engineer 12 2.50* (1.29-4.38) 5 2.20 (0.71-5.13)
Supervisor   3 1.74 (0.36-5.09) 7 1.68 (0.67-3.45)
Utility   1 0.84 (0.02-4.70) 1 0.80 (0.02-4.44)
Assembly 
  manufacturing 
  worker
Operator   2 7.07 (0.86-25.54) 16 0.93 (0.53-1.51)
Service engineer   3 2.53 (0.52-7.40) 0 0 (0.00-2.92)
Process engineer   1 1.40 (0.04-7.79) 0 0 (0.00-22.86)
Supervisor   0 0 (0.00-7.86) 0 0 (0.00-2.24)
Utility   0 0 (0.00-20.34) 0 0  (0.00-10.22)
Hire date < 1991 12 1.85 (0.95-3.23) 5 1.11 (0.36-2.60)
1992-1997 20 2.78* (1.70-4.30) 41 1.23 (0.88-1.67)
1998-2003   6 1.84 (0.68-4.01) 13 0.66 (0.35-1.13)
≥ 2004   0 0 (0.00-3.32) 3 0.61 (0.13-1.78)
Years worked 1 month-1 year   2 4.00 (0.48-14.45) 4 0.76 (0.21-1.94)
1-5 year   4 1.46 (0.40-3.73) 16 0.74 (0.42-1.20)
5-10 year   9 1.89 (0.86-3.58) 21 0.96 (0.59-1.47)
≥ 10 year 23 2.30* (1.46-3.46) 20 1.67* (1.02-2.59)
Obs: observed, SIR: standardized incidence ratio, CI: confidence interval, FAB: fabrication.
*Statistically significant at the 2-sided 5% level of significance.
†The total might be less or more than the sum of the number of cases at each stratum because there were workers who were classified into 
more than one stratum or classified as unknown.
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compatible to the UK study. It is possible that the healthy 
worker effect that was related to mortality was more profound 
in male workers than in female semiconductor workers. How-
ever, we are unable to explain why there was no difference in 
the overall incidence ratios. 
Leukemia
Leukemia was the main cancer of public concern. Leukemia 
incidence was lower than expected (cases = 8, SIR 0.69, 95% 
CI 0.30-1.37) in males but not significant, and higher than 
expected (cases = 10, SIR 1.28, 95% CI 0.61-2.36) in females 
but also not significant. In the subgroup mortality analysis, the 
cases in each group were too small to detect any findings.
The risk of leukemia in the previous studies did not show 
consistent results. A cohort study in the UK Midland region 
[16] reported elevated incidence in males (cases = 1, SIR 1.59) 
and a lower than expected level in females (cases = 2, SIR 0.80, 
95% CI 0.10-2.91), but the number of  observations were too 
small. The UK National Semiconductor investigation [14] by 
the Health and Safety Executive (HSE) could not calculate the 
SMR and SIR because there was only one case of leukemia. A 
study at the US firm IBM reported that leukemia mortality was 
lower than expected (SMR 0.91, 95% CI 0.70-1.18) for workers 
in 2 semiconductor companies [6]. Another study at the same 
firm [8] showed a slightly high proportional cancer mortality 
ratio (PCMR) for leukemia for males (1.13, 95% CI 1.02-1.26) 
and for females (1.13, 95% CI 0.90-1.44). A US study that in-
cluded multiple semiconductor facilities showed slightly lower 
leukemia mortality than expected (SMR 0.77, 95% CI 0.54-
1.07) [17]. In a Taiwan study [15], significantly elevated mortal-
ity (SMR 3.33, 95% CI 1.08-7.77) was shown in male workers 
with a 5-year lag period.
The results of the present study and previous studies did 
not show strong evidence of a risk for leukemia. Leukemia is 
a very rare cancer, so a large cohort size and sufficient follow-
up time are needed to observe meaningful findings. However, 
the majority of semiconductor studies, including this study, are 
limited by a small number of cases, so results are inconclusive. 
Female NHL
Mortality for NHL was higher than expected in males (deaths 
= 5, SMR 1.33, 95% CI 0.43-3.09) and females (deaths = 4, 
SMR 2.50, 95% CI 0.68-6.40), but not statistically significant. 
The incidence of NHL was significantly higher than expected 
in females (cases = 13, SIR 2.31, 95% CI 1.23-3.95) but was 
in line with expectations in males (cases = 10, SIR 0.93, 95% 
CI 0.45-1.71). In the subgroup analysis of females, the SIR for 
manufacturing workers was higher than that of  office work-
ers, and the SIR for assembly workers was higher than that of 
fabrication workers among manufacturing workers. Incidences 
in groups with short work durations and those most recently 
employed were significantly higher than expected. This pattern 
reversal of the relationship between exposure duration and can-
cer incidence did not support the presence of an occupational 
carcinogen. The semiconductor industry has developed very 
rapidly, and concerns about hazards or negative health effects 
were particularly focused on older technology. But the pos-
sibility of  work relatedness of  NHL in semiconductor work-
ers could not be ignored because subgroup analysis had more 
uncertainty for low numbers of person-years, and employment 
duration or employment year could not substitute for exposure 
level completely. In females, the portion of  employees who 
worked for long periods was very small. For instance, workers 
who had worked over 10 years were accounted for less than 
10% of the female cohort. This might be an explanation for the 
unstable result for subgroup analysis based on work duration. 
Previous studies on semiconductor workers have inconsis-
tently reported positive findings for NHL. Study at the US IBM 
firm reported that mortality for NHL was at the expected level 
(SMR 1.02, 95% CI 0.80-1.27) for workers in 2 semiconductor 
companies [6]. Another study at the same firm [8] reported a 
high proportional mortality ratio (PMR) and PCMR for both 
men (PMR 1.50, 95% CI 1.37-1.66, PCMR 1.36, 95% CI 
1.23-1.49) and women (PMR 1.39, 95% CI 1.11-1.76, PCMR 
1.22, 95% CI 0.97-1.54), but these findings need careful con-
sideration because PMR and PCMR studies are based on only 
deceased subjects. Mortality for smoking-related cancer was 
significantly low in the IBM cohort studies [6], so PMRs or 
PCMRs for cancers at other site might be affected. PMR and 
PCMR findings need to be interpreted cautiously because an 
observed significant excess proportion could be caused either 
by a true elevated risk in the disease or by another disease 
having a substantially reduced proportion. A US study that 
included multiple semiconductor companies showed a lower 
than expected level of NHL (SMR 0.69, 95% CI 0.48-0.97) [17].
The main occupational risk factors for NHL that were 
studied include exposure to pesticides, solvents (for example 
benzene, trichloroethylene [TCE]), and radiation. But the re-
ports on the NHL risk of  these occupational factors are not 
consistent and there is no definite occupational risk factor for 
NHL known so far [18,19]. For this reason and the lack of in-
dividual exposure data, in this cohort study we were not able to 
explore the causative agents in semiconductors in Korea. In or-
der to clarify the work-related risk of NHL, detailed toxicologi-
cal explanations and experimental and epidemiological studies 
would be required.
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Risks for NHL and leukemia showed marked gender dif-
ferences. There is a job discrepancy between males and females, 
in that the portion of manufacturing workers among females is 
much larger than that among males. In the case of leukemia, 
this difference comparatively decreased in the analysis that re-
stricted to manufacturing workers, but the gender difference for 
NHL risk did not decrease in the subgroup analysis and it was 
more profound in assembly manufacturing workers. Generally, 
female workers are engaged in assembly line and male workers 
maintain equipment required for production. But compared 
to workers in fabrication process, those in the assembly pro-
cess have lower potential exposures to chemicals and it is not 
thought that there were potential exposure differences between 
males and females.
Male thyroid cancer
There was no death that resulted from thyroid cancer, but male 
incidence was significantly higher than expected (cases = 38, 
SIR 2.11, 95% CI 1.49-2.89). In females, the incidence was as 
expected (cases = 62, SIR 0.99, 95% CI 0.76-1.27). In the sub-
group analysis of  male workers, incidences were higher than 
expected in office and manufacturing workers, employees hired 
before 1998, and those employed for more than 10 years. The 
SIR for office workers was higher than that of manufacturing 
workers. SIRs of groups divided by employed years tended to 
increase in groups with long periods of  work. Because high 
incidence ratios were distributed over various subgroups, it was 
hard to select suspected at-risk work groups.
There are few studies available that present the thyroid 
cancer risk in semiconductor industry workers. A study at the 
US firm IBM [7] reported that the incidence for thyroid cancer 
was lower than or the same as expected (SMR 0.71, 95%CI 
0.43-1.11) for workers in an IBM facility that made semicon-
ductors. Another study at the US firm IBM [8] showed a high 
PCMR for both men (PCMR 1.91, 95% CI 1.43-2.56) and 
women (PCMR 1.51, 95% CI 0.82-2.78). A US study including 
multiple semiconductor companies showed expected levels of 
thyroid cancer (SMR 0.66, 95% CI 0.02-3.67) [17]. 
Thyroid cancer is a common endocrine tumor and a well 
known risk factor for thyroid cancer is ionizing radiation [20]. 
Semiconductor manufacturers have an ‘Implant’ process in 
which workers have the possibility of  radiation exposure. In 
this cohort study, we could not separate workers in radiation-
related process. But it is not presumed that thyroid cancer cases 
were clustered in specific process because there were many 
cases in the office worker group. As for the NHL finding, a 
detailed analysis regarding toxicological explanations and a 
nested case-control study will be needed.
Thyroid cancer is regarded as a disease easily affected 
by over diagnosis bias or detection bias in epidemiological 
research. Some researchers thought that the rapid increase of 
thyroid cancer incidence worldwide was associated with an 
increased detection rate [21]. The possibility of detection bias 
is supported by the fact that subjects were mostly from the high 
SES population. High incidence in male office workers and 
highly educated groups (data not shown) might be associated 
with this result. But there is no definitive evidence of detection 
bias. 
Other specific cancer
Although it was not statistically significant, the SIR of kidney 
cancer increased in males (cases = 13, SIR 1.82, 95% CI 0.97-
3.12) and this was marginally significant. But there were no 
cases of  kidney cancer in females. Previous studies did not 
show consistent results for kidney cancer. The UK Midland re-
gion study [16] reported elevated incidence in females (cases = 
4, SIR 1.31, 95% CI 0.36-3.36) and there was no case observed 
in males. A study at the US firm IBM reported that kidney 
cancer mortality was at the expected level (SMR 0.95, 95% 
CI 0.69-1.29) for workers in the 2 semiconductor companies 
[6]. Another study at the same firm [8] showed a slightly high 
proportional cancer mortality ratio (PCMR) for kidney cancer 
for both men (PCMR = 1.36, 95% CI 1.21-1.53) and women 
(PCMR = 1.20, 95% CI 0.85-1.70). A US study that included 
multiple semiconductor facilities showed slightly lower kidney 
cancer mortality than expected (SMR 0.74, 95% CI 0.46-1.14) 
[17]. The UK National Semiconductor investigation [14] by the 
HSE analyzed the combined risk of genitourinary cancer and 
the incidence was lower than expected in both males (cases = 
11, SIR = 0.82, 95% CI 0.41-1.47) and females (cases = 11, SIR 
= 0.67, 95% CI 0.33-1.20). 
The incidence of malignant melanoma was considerably 
higher than expected in males (SIR = 2.9, 95% CI 0.60-8.47), 
although the confidence interval was very wide. This result 
was based on only 3 cases and there were no cases observed in 
females. Though the evidence is inconclusive, these results with 
large effect estimates should be noticed and be followed-up.
Strengths and weaknesses
This study is an investigation of the semiconductor industry in 
Korea, which means that it covers all major companies with a 
wafer fabrication process; therefore, selection bias due to geo-
graphic restriction was limited. Studies conducted in the UK 
National Semiconductor could not extend to the entire indus-
try in the UK because pre-existing evidence was not enough 
to justify the commitment of resources [5]. Studies in the US 
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firm IBM were also limited to eligible companies [6,7,17], and 
results may have been geographically biased. Our study was 
conducted by OSHRI of KOSHA, on behalf  of the Ministry 
of Employment and Labor in Korea under the Occupational 
Safety and Health Act.
An additional strength of  this study is the large number 
of  study subjects in the fabrication process. The numbers of 
workers for mortality and incidence analyses in our study were 
113,443 and 108,933, respectively, and person-years of  mor-
tality and incidence were 832,512 and 718,849, respectively. 
In the UK, the HSE study was conducted on 4,388 workers 
and 55,014 person-years in 2003 and it was updated in 2010 
to 84,733 person-years [14]. Studies on the East Fishkill and 
Burlington factories in the US had larger numbers of workers 
(45,492 and 29,962, respectively) and person-years (813,961 
and 464,390, respectively). In the Taiwan study, the number 
of  workers was 47,426 [15]. Therefore, our cohort included 
relatively large numbers of workers compared with other stud-
ies. We also tried to assess non-fatal and fatal cancers for SMR 
and SIR calculations. The most recently reported study on the 
semiconductor industry in the US was conducted on 100,081 
workers with 1,490,486 person-years [17]. However, only 
37,225 workers that were involved in the fabrication process 
were assessed. 
There were also limitations in our study. The cohort was 
built in 1998, but almost all the factories were established before 
1998, so many earlier workers were excluded from the cohort. 
In the case that there were cancer deaths or occurrences in the 
workers retired before 1998, there could be an underestimate of 
the cancer risk because of the healthy worker survival effect. To 
consider this limitation, the year of 1998 was used to classify 
employees in subgroup analysis with respect to the hired dates 
of  workers. It is assumed that all of  the unmatched workers 
with the death or cancer registry remained alive at the end of 
the study. These registries covers nearly the entire nation, but 
if  some of the workers had emigrated from Korea to another 
country after retirement and there were deaths or cancer occur-
rences among them during the study period, then the mortality 
rate or incidence rate of this cohort would be artificially low-
ered. But the emigration rate of Korean people has been very 
low (lower than 0.04% per year from 2002 to 2008) [22], so it is 
expected that underestimation of the risk due to this aspect is 
not strong. The observed period (6.6 years for incidence and 7.5 
years for mortality) was not long enough to obtain stable results 
of  cancer risk. In the UK National Semiconductor study, the 
mean length of follow-up was 12.5 years [5], and the US IBM 
factories were studied for more than 30 years [6]. In the pres-
ent study, the majority of the subjects were young at the end of 
follow-up and cases were sparse for subgroups because of the 
long latency of cancer development.
There might be a possibility of  misclassification for job 
groups because subjects were categorized by researchers and 
company staff  based on the name of the department and job 
on the employment records. Information relating to non-occu-
pational risk factors, like family history, was not considered and 
occupational exposure to specific agents on the personal level 
were not available. Information on the list of chemicals and ex-
posure levels were reported in other studies [23]. We did not at-
tempt to analyze data using internal comparison because of the 
small size of the office worker group; therefore, there might be 
a potential distortion due to the healthy worker effect and selec-
tion bias, like the detection bias from the relatively high SES.
In conclusion, there was no significant increase of leuke-
mia in the semiconductor industry in Korea. However, NHL 
in females and thyroid cancer in males were significantly 
increased even though there was no definitive association be-
tween work and those diseases in subgroup analysis by work 
duration. This result should be interpreted cautiously and lon-
ger follow-up study is needed, because the majority of the co-
hort was young and the number of cases was very small. Also, 
a nested case-control study for female NHL and male thyroid 
cancer is needed to clarify the work-related risk of the cancers. 
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